Study | TB characteristics | Median CD4 count | Study arms | Mortality difference | Country | ART regimen |
---|---|---|---|---|---|---|
(1A) SAPIT 1 Abdool Karim et al. NEJM 2010 [43] | Smear +ve pulmonary TB | 150 | Integrated vs. sequential | 5 vs. 12 deaths/100 PYs 56Â % lower in integrated arm | South Africa | ddI, 3TC, EFV |
(1B) SAPIT 2 Abdool Karim et al. NEJM 2011 [44] | Smear +ve pulmonary TB | 150 | 4 vs. 8–12 weeks | No differences of AIDS/death Lower in only CD4 <50 8 vs. 26 deaths/100 PYs | South Africa | ddI, 3TC, EFV |
(2) CAMELIA Blanc et al. NEJM 2011 [42] | Smear +ve pulmonary TB | 25 | 2 vs. 8Â weeks | 15 vs. 26Â % 38Â % lower in 2-week arm | Cambodia | d4T, 3TC, EFV |
(3) STRIDE Havlir et al. NEJM 2011 [45] | Confirmed or probable pulmonary TB | 77 | <2 vs. 8–12 weeks | No differences of mortality Lower in only CD4 <50 15 vs. 27 % | Multi-national | TDF/FTC, EFV |
(4) TOROK Torok et al. CID 2011 [49] | TB meningitis | 41 | <2 vs. 8Â weeks | No differences of time to death | Vietnam | AZT, 3TC, EFV |
(5) TIME Manosuthi et al. JAIDS 2012 [46] | Confirmed or probable any TB | 43 | 4 vs. 12Â weeks | Have a tendency in CD4 <50 10 vs. 14 deaths/100 PYs | Thailand | TDF, 3TC, EFV |
(6) TB-HAART Mfinanga et al. Lancet ID 2014 [48] | Culture-confirmed TB | 367 | ≤2 weeks vs. 6 months | No difference between early and late ART on composite endpoint of death, tuberculosis treatment failure, and recurrence | South Africa, Uganda, Zambia, Tanzania | AZT, 3TC, EFV |